A custom nanobody discovery platform takes a defined target and develops candidate nanobodies through a planned sequence of library generation, selection, screening, and validation. For veterinary medicine, the workflow can support research into diagnostic reagents and other target-binding tools for animal health applications. The best route depends on the target’s properties, intended use, available samples, and whether an immune, naïve, or synthetic library is appropriate. Before starting, buyers should agree with the supplier on project scope, success criteria, deliverables, and the evidence required to evaluate candidate binders.
Click here to get more.
This guide is for veterinary diagnostics developers, animal-health researchers, biotechnology companies, and procurement teams considering a custom nanobody project. It is also useful for groups that have a target but are unsure how to translate it into a discovery plan. The workflow described here is a general framework rather than a guarantee of project duration or outcome. Specific methods and decision points should be agreed with the discovery provider.
Nanobodies are single-domain antibody fragments based on the variable domain of heavy-chain-only antibodies found in camelids. A typical VHH is approximately 12–15 kDa and around 110–130 amino acid residues, although exact values vary by sequence. Their compact, single-domain structure can be useful when researchers need a small binding reagent or want to explore formats that differ from conventional antibodies. Binding performance and suitability still need to be established for each target and intended application.
A custom discovery platform connects target preparation with candidate identification and downstream testing. It may use an immune library generated after immunization, a naïve library containing diverse binders, or a synthetic library built from designed sequence diversity. The choice is not simply a matter of preference: target availability, project constraints, desired diversity, and the discovery provider’s capabilities all matter. A supplier should explain why its proposed route fits the project rather than presenting one workflow as universally optimal.
Start by describing the target, its biological context, and the application the candidate is expected to serve. For veterinary work, this might include detecting a pathogen-associated protein, measuring an animal biomarker, or supporting laboratory research on a toxin or receptor. Clarify whether the target is purified, recombinant, cell-associated, or available only in a complex sample. Also identify likely cross-reactivity concerns, such as related proteins from different animal species or pathogen strains.
The supplier should review target identity, purity, format, concentration, and handling requirements before recommending a discovery route. An immune-library approach may be considered when an immunization program is appropriate and the project timeline and animal-use requirements allow it. Naïve or synthetic libraries may be alternatives when immunization is not suitable or when the project needs a different source of sequence diversity. Selection plans often use 2–4 rounds of enrichment as an initial framework, but the number and conditions should be adjusted to the target and observed results.
In a common phage-display workflow, displayed nanobodies are exposed to the target, non-binding material is washed away, and target-associated candidates are recovered for further selection. Screening then helps distinguish candidate binders from clones that bind nonspecifically or perform poorly in the assay format. A credible plan should include controls appropriate to the target, such as an unrelated protein or a relevant negative sample where available. The exact assay design should reflect whether the intended use is, for example, purified-protein binding or recognition of a target in a more complex veterinary sample.
Promising clones are typically sequenced and expressed in a suitable format for confirmation. Characterization can assess properties such as binding signal, specificity, expression, and behavior under the conditions relevant to the intended use. These results are not interchangeable: a candidate that binds purified antigen may not perform as needed in serum, tissue, or a diagnostic assay. Ask the supplier which experiments are included, which are optional, and what raw data or reports will be delivered.
Link to NBbiolab
Discovery is not the same as product validation. A veterinary diagnostic developer may need further testing with representative samples, relevant species, and the final assay configuration. A research-use candidate may require different evidence from a reagent intended for a regulated diagnostic or therapeutic program. Agree in advance on what constitutes a useful candidate and what additional work will be needed before commercial or clinical use.
| Project need | Potential use | Key question for the discovery plan |
|---|---|---|
| Pathogen-associated target | Research assays or diagnostic reagent development | Will the binder recognize relevant strains and target forms? |
| Animal biomarker | Laboratory measurement or assay development | Can specificity be assessed against related proteins and sample components? |
| Cell-surface target | Cell-based research or target characterization | Can selection and screening preserve access to the native target structure? |
| Toxin or other soluble target | Research and candidate-reagent development | What binding and functional testing is appropriate for the intended purpose? |
These are potential research and development applications, not assurances that a discovered binder will perform in a finished assay or be suitable for treatment. For diagnostics, sample matrix effects, detection limits, and cross-reactivity require application-specific evaluation. For therapeutic research, additional functional, safety, and regulatory work is necessary. Buyers should describe the intended species and use early so the supplier can plan relevant controls and follow-up testing.
Before requesting a quote, assemble available information on target sequence, species, structure, expression system, and sample format. Note whether the target is expected to be glycosylated, membrane-bound, or part of a protein complex, as these features can affect antigen presentation and screening. If the final assay uses a specific matrix or detection format, explain that at the outset. Better-defined inputs help the supplier identify risks before work begins.
“Custom discovery” can describe different scopes, so compare proposals by their included activities and outputs. Ask whether the service covers target review, library selection or construction, enrichment, clone screening, sequence identification, expression, and characterization. Confirm how many candidates are expected to be reported as a project goal, not as a guaranteed result, and what happens if the initial screen produces no suitable leads. Clarify ownership, sequence disclosure, material transfer, and options for follow-on optimization in the commercial terms.
Pricing depends on factors such as target complexity, library route, immunization requirements, screening depth, and the number of candidates to express or characterize. Minimum order quantities may apply to supplied proteins, expressed nanobodies, or follow-on production, so confirm whether they are relevant to the discovery phase or only to later manufacturing. Lead time should be quoted against the agreed scope and project dependencies, including target readiness and any required animal procedures. We recommend requesting a staged quotation that separates core discovery from optional validation or optimization.
Ask for a written scope and review it with both technical and procurement stakeholders. A supplier should distinguish established capabilities from optional work and avoid promising performance that has not yet been tested. Where animal immunization is proposed, discuss the applicable ethical review and project requirements rather than assuming they are identical across locations. Clear expectations reduce avoidable changes after the project starts.
The right custom nanobody discovery workflow is the one matched to your target, veterinary application, and evidence requirements. Begin by preparing a target summary, available antigen information, intended species, sample type, and a short description of the final use. At NBbiolab, we can discuss these inputs with your team and help scope a discovery and characterization plan for review. Contact us with your project requirements to request a tailored proposal and clarify the next steps.
For more Custom Nanobody Discovery Platforminformation, please contact us. We will provide professional answers.